[Pharmacoeconomic analysis of dabigatran etexilate effectiveness in patients with nonvalvular atrial fibrillation].
Iu B
IuB
Belousov
V Iu
VIu
Mareev
I S
IS
Iavelov
D Iu
DIu
Belousov
E V
EV
Afanas'eva
D000925:Anticoagulants / Q000191:economics / Q000627:therapeutic use; D001241:Aspirin / Q000191:economics / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000150:complications / Q000191:economics; D001562:Benzimidazoles / Q000191:economics / Q000627:therapeutic use; D001777:Blood Coagulation / Q000187:drug effects; D001780:Blood Coagulation Tests / Q000379:methods; D000077144:Clopidogrel; D003365:Costs and Cost Analysis / Q000379:methods / Q000706:statistics & numerical data; D000069604:Dabigatran; D006801:Humans; D007356:Insurance, Pharmaceutical Services / Q000706:statistics & numerical data; D015233:Models, Statistical; D010043:Outcome and Process Assessment, Health Care / Q000379:methods / Q000706:statistics & numerical data; D011725:Pyridines / Q000191:economics / Q000627:therapeutic use; D012426:Russia; D013923:Thromboembolism / Q000097:blood / Q000188:drug therapy / Q000191:economics / Q000209:etiology; D013988:Ticlopidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000191:economics
D000925:Anticoagulants; D001562:Benzimidazoles; D011725:Pyridines; D000077144:Clopidogrel; D000069604:Dabigatran; D013988:Ticlopidine; D001241:Aspirin